FDA criticizes Aventis for Ketek study failures

Aventis allowed a clinical trial of Ketek to proceed uncorrected despite its own audits that revealed "serious protocol violations and regulatory noncompliance by multiple clinical investigators." In a letter to Sanofi-Aventis, regulators severely criticized Aventis for not throwing doctors out of the study or informing the FDA. The FDA approved Ketek back in 2004. Ketek has since been linked to an increased risk of liver damage, and the questionable study was designed to investigate the drug's potential side effects, including liver damage. One doctor responsible for one site involved in the study was subsequently convicted of fraud. Sanofi-Aventis says the company acted in good faith and plans a detailed response, but that's hardly likely to mollify the company's critics.

- see the FDA release
- here's the article from The Wall Street Journal

Related Articles:
Sanofi underscores pipeline advances, setbacks. Report
FDA panel votes to restrict Ketek. Report
Senator makes dramatic demand in Ketek probe. Report
Sanofi's Ketek could cause liver problems. Report

Suggested Articles

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.

Merck will apply its vaccine capabilities to an asset based on Themis’ measles vector platform that is set to enter the clinic this year.